• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [520 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2018 National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NICE technology appraisal guidance 531
2018 National Institute for Health and Care Excellence (NICE) Alectinib for untreated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 536
2018 Andalusian Health Technology Assessment Area (AETSA) Alectinib as monotherapy for the first-line treatment of adult patients with ALK positive advanced non-small cell lung cancer. EUnetHTA adopted HTA report
2018 Agency for Healthcare Research and Quality (AHRQ) Patient navigation models for lung cancer
2018 NIHR Health Technology Assessment programme UK Lung Cancer Screening Trial (UKLS) - Feasibility study and protocol development
2018 European Network for Health Technology Assessment (EUnetHTA) Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
2018 Basque Office for Health Technology Assessment (OSTEBA) [Effectiveness and safety of bone suppression technology for the detection of lung cancer and indications for its use]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Addendum to A17-50]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Atezolizumab in non-small cell lung cancer]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018 NIHR Health Technology Assessment programme Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
2017 National Institute for Health and Care Excellence (NICE) Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 436
2017 National Institute for Health and Care Excellence (NICE) Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 438
2017 National Institute for Health and Care Excellence (NICE) Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 444
2017 HAYES, Inc. GeneStrat (Biodesix Inc.)
2017 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge in support of the decision to integrate new endobronchial ultrasound (EBUS) services in Québec hospitals]
2017 Institute for Clinical Effectiveness and Health Policy (IECS) [Nintedanib in lung cancer]
2017 Institute for Clinical Effectiveness and Health Policy (IECS) [Ceritinib in lung cancer]
2017 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)
2017 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer
2017 Agency for Care Effectiveness (ACE) Gemcitabine for the treatment of cancer
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (lung cancer): Addendum to Commission A16-62]
2017 Andalusian Health Technology Assessment Area (AETSA) Utility of pulmonary metastases resection for colorectal cancer
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-small cell lung cancer) - Addendum to Commission A17-06]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2017 HAYES, Inc. Proton beam therapy for non-small cell lung cancer
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (lung cancer) - Addendum to Commission A17-20]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017 Institute for Clinical Effectiveness and Health Policy (IECS) [Lung cryobiopsy in diffuse interstitial lung disease diagnosis]
2017 National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 428
2016 Agency for Healthcare Research and Quality (AHRQ) Imaging for the pretreatment staging of small cell lung cancer
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib: addendum to commission A15-59]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib: benefit assessment according to §35a Social Code Book V]
2016 NIHR Horizon Scanning Centre (NIHR HSC) Lefitolimod for extensive small cell lung cancer – maintenance therapy
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Necitumumab - Benefit assessment according to §35a Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (new therapeutic indication) - benefit assessment according to §35a SGB V]
2016 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Low-dose computed tomography screening for lung cancer]
2016 NIHR Horizon Scanning Centre (NIHR HSC) Afatinib (Giotrif) for advanced or metastatic, squamous non-small cell lung cancer progressing on or after platinum-based chemotherapy
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Necitumumab (lung cancer) - Addendum to Commission A16-17]
2016 HAYES, Inc. VeriStrat
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC) - Addendum to Commission A16-25]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib (new therapeutic indication) - Benefit assessment according to §35a SGB V]
2016 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Microwave tissue ablation of primary and secondary lung cancer
2016 The Regional Health Technology Assessment Centre (HTA-centrum) Positron emission tomography and computed tomographic imaging prior to radiotherapy for lung cancer
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2016 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy
2016 NIHR Horizon Scanning Centre (NIHR HSC) myPlan™ test for early-stage lung adenocarcinoma prognosis
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (lung cancer): benefit assessment according to §35a Social Code Book V; expiry of the decision
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib (lung cancer) - Benefit assessment according to §35a Social Code Book V]
2016 NIHR Horizon Scanning Centre (NIHR HSC) Capmatinib for advanced, EGFR wild type, c-Met amplified, non-small cell lung cancer – second or third line
2016 NIHR Horizon Scanning Centre (NIHR HSC) Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer – first line
2016 NIHR Horizon Scanning Centre (NIHR HSC) Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer – first line
2016 HAYES, Inc. Novocure (tumor treating fields)
2016 NIHR Horizon Scanning Centre (NIHR HSC) Tremelimumab for unresectable pleural or peritoneal malignant mesothelioma – second and third line
2016 HAYES, Inc. Nivolumab (Opdivo) for treatment of non-small cell lung cancer
2016 Technology Assessment Unit of the McGill University Health Centre (MUHC) A mini-health technology assessment of Linear and Radial Endobronchial Ultrasound (EBUS) and Electromagnetic Navigation Bronchoscopy (ENB) in the diagnosis and staging of lung cancer in adults
2016 NIHR Horizon Scanning Centre (NIHR HSC) Crizotinib (Xalkori) for advanced ROS1 positive non-small cell lung cancer – first line
2016 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)
2016 NIHR Horizon Scanning Centre (NIHR HSC) Ceritinib (Zykadia) - non-small cell lung cancer: locally advanced or metastatic; anaplastic lymphoma kinase (ALK) positive – first line
2016 National Institute for Health and Care Excellence (NICE) Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer. NICE technology appraisal guidance 395
2016 NIHR Health Technology Assessment programme The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
2016 National Institute for Health and Care Excellence (NICE) Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin. NICE technology appraisal guidance 402
2016 National Institute for Health and Care Excellence (NICE) Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 403
2016 National Institute for Health and Care Excellence (NICE) Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 406
2016 National Institute for Health and Care Excellence (NICE) Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 411
2016 Institute for Clinical Effectiveness and Health Policy (IECS) Nivolumab for the treatment of non-small cell lung cancer
2016 Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of care times for the main cancer sites: colon/rectum, lung, breast and prostate]
2016 National Institute for Health and Care Excellence (NICE) Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 422
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab - Addendum to Commission A15-32]
2016 NIHR Horizon Scanning Centre (NIHR HSC) Dabrafenib (Tafinlar) and trametinib (Mekinist) combination therapy for advanced BRAF mutated non-small cell lung cancer
2015 NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) for PD-L1 strong-positive metastatic non-small cell lung cancer – first line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Dacomitinib for locally advanced or metastatic EGFR positive non-small cell lung cancer – first line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Crizotinib (Xalkori) for ALK-positive, locally advanced or metastatic, non-small cell lung cancer — first line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Ipilimumab (Yervoy) with paclitaxel and carboplatin for stage IV or recurrent non-small cell lung cancer
2015 NIHR Horizon Scanning Centre (NIHR HSC) Rociletinib for advanced or recurrent non-small cell lung cancer with the EGFR T790M mutation
2015 NIHR Horizon Scanning Centre (NIHR HSC) Selumetinib for KRAS mutation-positive advanced non-small cell lung cancer – second line
2015 Institute for Clinical Effectiveness and Health Policy (IECS) [Ceritinib for the treatment of ALK-positive metastatic non-small cell lung cancer]
2015 NIHR Horizon Scanning Centre (NIHR HSC) Texture analysis of Radiological images (TexRAD) for lung cancer assessment
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer
2015 Andalusian Health Technology Assessment Area (AETSA) Active immunotherapy for lung cancer. Systematic review.
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 National Institute for Health and Care Excellence (NICE) Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer. NICE technology appraisal guidance 347
2015 New Zealand National Health Committee (NHC) Epidermal growth factor receptor gene mutation analysis testing assessment
2015 National Institute for Health and Care Excellence (NICE) Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 362
2015 NIHR Horizon Scanning Centre (NIHR HSC) AZD9291 for locally advanced or metastatic, EGFR and T790M mutation positive non-small cell lung cancer – second line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Ipilimumab (Yervoy) for small cell lung cancer – first line, in combination with etoposide and platinum therapy
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 HAYES, Inc. Cryoablation for treatment of non-small cell lung cancer